MX337258B - Compuestos utiles para tratar sindrome de inmunodeficiencia adquirida (sida). - Google Patents
Compuestos utiles para tratar sindrome de inmunodeficiencia adquirida (sida).Info
- Publication number
- MX337258B MX337258B MX2013006322A MX2013006322A MX337258B MX 337258 B MX337258 B MX 337258B MX 2013006322 A MX2013006322 A MX 2013006322A MX 2013006322 A MX2013006322 A MX 2013006322A MX 337258 B MX337258 B MX 337258B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- nrarb
- hydrogen atom
- nra
- treating aids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula (I) para uso como un agente que previene, inhibe o trata el SIDA. La presente invención además se refiere a compuestos de fórmula (I), en donde: X es CR0 o N; R0, R1, R2, R3, R4, R7 y R8 representan independientemente un átomo de hidrógeno, un átomo de halógeno o un grupo elegido entre un grupo alquilo (C1-C5), un grupo cicloalquilo (C3.C6), un grupo fluoroalquilo (C1-C5), un grupo alcoxi (C1-C5), un grupo fluoroalcoxi (C1-C5), un grupo -CN, un grupo COORa, un grupo -NO2, un grupo -NRaRb, un grupo -NRa-SO2-NRaRb, un grupo -NRa- SO2Ra, un grupo -NRa-C (=O) -Ra, un grupo -NRaC (=O) -NRaRb, un grupo -SO2-NRaRb, un grupo -SO3H, un grupo -OH, un grupo -O- SO2-ORc, un grupo -O-P(=O) - (ORc) (ORd), un grupo -O-CH2-COORc y puede ser además un grupo elegido entre: (Ila), (IIIa), R5 representa un átomo de hidrógeno, un grupo alquilo (C1-C5) o un grupo cicloalquilo (C3-C6); R10 es un átomo de hidrógeno o un átomo de cloro, y R11 es un átomo de hidrógeno o un grupo alquilo (C1-C4), o cualquiera de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10306417A EP2465502A1 (en) | 2010-12-15 | 2010-12-15 | Compounds useful for treating AIDS |
PCT/IB2011/055643 WO2012080953A1 (en) | 2010-12-15 | 2011-12-13 | Compounds useful for treating aids |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013006322A MX2013006322A (es) | 2013-10-25 |
MX337258B true MX337258B (es) | 2016-02-22 |
Family
ID=43755105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006322A MX337258B (es) | 2010-12-15 | 2011-12-13 | Compuestos utiles para tratar sindrome de inmunodeficiencia adquirida (sida). |
Country Status (19)
Country | Link |
---|---|
US (1) | US9061999B2 (es) |
EP (2) | EP2465502A1 (es) |
JP (1) | JP6049630B2 (es) |
KR (1) | KR101749232B1 (es) |
CN (1) | CN103415290B (es) |
AR (1) | AR084277A1 (es) |
AU (1) | AU2011342826B2 (es) |
BR (1) | BR112013014943B1 (es) |
CA (1) | CA2819317C (es) |
CU (1) | CU20130080A7 (es) |
DK (1) | DK2651416T3 (es) |
ES (1) | ES2681539T3 (es) |
HR (1) | HRP20181190T1 (es) |
MX (1) | MX337258B (es) |
PL (1) | PL2651416T3 (es) |
PT (1) | PT2651416T (es) |
RU (1) | RU2598845C2 (es) |
WO (1) | WO2012080953A1 (es) |
ZA (1) | ZA201303922B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
HUE061262T2 (hu) | 2009-06-12 | 2023-05-28 | Abivax | Splicing mechanizmust gátló új kémiai molekulák splicing hibákból betegségek kezelésére |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
CN105530938B (zh) * | 2013-07-05 | 2019-10-22 | Abivax公司 | 用于治疗由逆转录病毒引起的疾病的化合物 |
EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP2975034A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
WO2017034986A1 (en) * | 2015-08-21 | 2017-03-02 | University Of Kansas | Human tlr8-selective agonists |
PT3429998T (pt) | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
KR101966351B1 (ko) * | 2016-06-08 | 2019-04-08 | 한국과학기술연구원 | 히스톤 메틸전달효소 저해용 퀴놀린 유도체 및 이의 용도 |
JP2020525459A (ja) | 2017-06-26 | 2020-08-27 | アンスティテュ・パストゥール | Hivリザーバーを排除し、ウイルス負荷を低減する処置 |
WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
CN109776498B (zh) * | 2019-03-13 | 2020-04-07 | 浙江永宁药业股份有限公司 | 一种西洛他唑的制备方法 |
EP4063351A1 (en) * | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
WO2024109936A1 (zh) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种喹啉胺类化合物晶型及其制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2419199A (en) * | 1945-02-09 | 1947-04-22 | Parke Davis & Co | Quinoline compounds and process of making same |
FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
US4466965A (en) * | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
JPS59501318A (ja) * | 1982-07-26 | 1984-07-26 | アメリカン ホスピタル サプライ コ−ポレ−シヨン | ヘテロアリ−ル置換アミノメチルベンゼン誘導体 |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
EP1165064B1 (en) | 1999-04-05 | 2004-02-25 | City of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
CN1688545A (zh) | 2002-07-19 | 2005-10-26 | 记忆药物公司 | 磷酸二酯酶4抑制剂,包括n-取代的苯胺及二苯胺类似物 |
WO2006081444A2 (en) | 2005-01-28 | 2006-08-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
WO2004078731A1 (fr) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
WO2008115870A2 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
CN101679150B (zh) | 2007-05-17 | 2013-05-15 | Lg化学株式会社 | 蒽衍生物和使用该蒽衍生物的有机电子器件 |
KR20100053626A (ko) | 2007-08-15 | 2010-05-20 | 메모리 파마슈티칼스 코포레이션 | 5-ht6 수용체 친화성을 나타내는 3'-치환된 화합물 |
FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
HUE061262T2 (hu) | 2009-06-12 | 2023-05-28 | Abivax | Splicing mechanizmust gátló új kémiai molekulák splicing hibákból betegségek kezelésére |
-
2010
- 2010-12-15 EP EP10306417A patent/EP2465502A1/en not_active Withdrawn
-
2011
- 2011-12-13 MX MX2013006322A patent/MX337258B/es active IP Right Grant
- 2011-12-13 PL PL11805230T patent/PL2651416T3/pl unknown
- 2011-12-13 JP JP2013543948A patent/JP6049630B2/ja active Active
- 2011-12-13 AU AU2011342826A patent/AU2011342826B2/en active Active
- 2011-12-13 RU RU2013126947/04A patent/RU2598845C2/ru active
- 2011-12-13 WO PCT/IB2011/055643 patent/WO2012080953A1/en active Application Filing
- 2011-12-13 BR BR112013014943-4A patent/BR112013014943B1/pt active IP Right Grant
- 2011-12-13 KR KR1020137018457A patent/KR101749232B1/ko active IP Right Grant
- 2011-12-13 DK DK11805230.7T patent/DK2651416T3/en active
- 2011-12-13 EP EP11805230.7A patent/EP2651416B1/en active Active
- 2011-12-13 US US13/993,990 patent/US9061999B2/en active Active
- 2011-12-13 PT PT118052307T patent/PT2651416T/pt unknown
- 2011-12-13 ES ES11805230.7T patent/ES2681539T3/es active Active
- 2011-12-13 CA CA2819317A patent/CA2819317C/en active Active
- 2011-12-13 CN CN201180060026.XA patent/CN103415290B/zh active Active
- 2011-12-14 AR ARP110104670A patent/AR084277A1/es active IP Right Grant
-
2013
- 2013-05-29 ZA ZA2013/03922A patent/ZA201303922B/en unknown
- 2013-06-13 CU CUP2013000080A patent/CU20130080A7/es unknown
-
2018
- 2018-07-24 HR HRP20181190TT patent/HRP20181190T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201303922B (en) | 2014-07-30 |
KR20140041402A (ko) | 2014-04-04 |
KR101749232B1 (ko) | 2017-07-03 |
CN103415290B (zh) | 2016-09-14 |
BR112013014943A2 (pt) | 2016-09-13 |
CA2819317A1 (en) | 2012-06-21 |
EP2465502A1 (en) | 2012-06-20 |
US20130267703A1 (en) | 2013-10-10 |
RU2598845C2 (ru) | 2016-09-27 |
US9061999B2 (en) | 2015-06-23 |
DK2651416T3 (en) | 2018-08-06 |
CU20130080A7 (es) | 2013-08-29 |
PL2651416T3 (pl) | 2018-09-28 |
CA2819317C (en) | 2017-02-28 |
MX2013006322A (es) | 2013-10-25 |
BR112013014943A8 (pt) | 2018-06-12 |
EP2651416A1 (en) | 2013-10-23 |
AU2011342826A1 (en) | 2013-07-04 |
JP2013545798A (ja) | 2013-12-26 |
PT2651416T (pt) | 2018-07-30 |
CN103415290A (zh) | 2013-11-27 |
HRP20181190T1 (hr) | 2019-03-08 |
WO2012080953A1 (en) | 2012-06-21 |
BR112013014943B1 (pt) | 2022-05-03 |
JP6049630B2 (ja) | 2016-12-21 |
AR084277A1 (es) | 2013-05-02 |
AU2011342826B2 (en) | 2016-02-11 |
EP2651416B1 (en) | 2018-05-09 |
RU2013126947A (ru) | 2015-01-20 |
ES2681539T3 (es) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX337258B (es) | Compuestos utiles para tratar sindrome de inmunodeficiencia adquirida (sida). | |
TN2011000362A1 (en) | Pyridazinone compounds | |
CY1120066T1 (el) | Ενωση κινολονης | |
PH12014502117A1 (en) | Tetrazolinone compounds and its use as pesticides | |
UA107657C2 (uk) | Похідні бензофурану | |
NO20083408L (no) | Korrosjonsinhibitorer som har okt biologisk nedbrytbarhet og redusert giftighet | |
TW200639158A (en) | New compounds with therapeutic effect | |
MX2021006754A (es) | Derivados de quinoleina para el tratamiento de enfermedades inflamatorias. | |
NO20074057L (no) | 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer | |
MX2011007446A (es) | Combinaciones que comprenden metotrexato e inhibidores de dihidroorotato deshidrogenasa. | |
MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
NI200900164A (es) | COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA. | |
MX2009011769A (es) | Derivados de piridona como inhibidores de mapk p38a. | |
AR061806A1 (es) | Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d) | |
JO3143B1 (ar) | مركبات تتراهيدرو بيرولو ثيازين | |
MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
IN2012DN00770A (es) | ||
NZ712660A (en) | Dicarboxylic acid compound | |
MX2011014018A (es) | Pirazincarboxamidas como inhibidores de dgati. | |
CO6300944A2 (es) | Derivado de hidroxi-quinoxalin-carboxamida | |
MX2016003630A (es) | Compuestos heterociclicos de n-acilimino. | |
PH12018502720A1 (en) | Deoxidizing agent for boilers and method for deoxidizing boiler water system | |
GEP20156222B (en) | Pyrazole compound | |
RS53965B1 (en) | ACILBENZENA DERIVATIVES | |
MX2009012346A (es) | Compuestos organicos de azufre y su uso para controlar artropodos dañinos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ABIVAX |
|
FG | Grant or registration |